Breast Cancer
Jan 29, 2025, 22:27
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer
Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, shared on X:
“Phase 3 KEYNOTE756 trial –
1st interim analysis:
Pembro + chemo
pCR in high-risk early ER+/HER2− Breast Cancer (24.3% vs 15.6%)
Manageable safety
EFS data maturing. ”
Authors: Fatima Cardoso, Joyce O’Shaughnessy, Zhenzhen Liu, Heather McArthur, Peter Schmid, Javier Cortes, Nadia Harbeck, Melinda L. Telli, David W. Cescon, Peter A. Fasching, Zhimin Shao, Delphine Loirat, Yeon Hee Park, Manuel Gonzalez Fernandez, Gábor Rubovszky, Laura Spring, Seock-Ah Im, Rina Hui, Toshimi Takano, Fabrice André, Hiroyuki Yasojima, Yu Ding, Liyi Jia, Vassiliki Karantza, Konstantinos Tryfonidis, Aditya Bardia
Aditya Bardia
cancer
David W. Cescon
Delphine Loirat
Fabrice Andre
Fatima Cardoso
Gábor Rubovszky
Heather McArthur
Hiroyuki Yasojima
Javier Cortés
Joyce O'Shaughnessy
Konstantinos Tryfonidis
Kristina Jankovic
Laura Spring
Liyi Jia
Manuel Gonzalez Fernandez
Melinda L. Telli
Nadia Harbeck
OncoDaily
Oncology
Peter A. Fasching
Peter Schmid
Rina Hui
Seock-Ah Im
Toshimi Takano
Vassiliki Karantza
Yeon Hee Park
Yu Ding
Zhenzhen Liu
Zhimin Shao
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 29, 2025, 22:27
Jan 29, 2025, 22:26
Jan 29, 2025, 22:26